Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2019 / Articles / Feb / Owner of a Lonely Heart
Discovery & Development Formulation Dosage Forms

Owner of a Lonely Heart

By Jessica Finlay 02/18/2019 0 min read Quick Read (pre 2022)

Share

In 2018, the UK’s government appointed its first Minister for Loneliness. The role: to tackle loneliness (defined as an affective state reflecting the subjective experience of feeling alone or lonely) and social isolation (a measurable lack of social relationships) in Britain. Though the role may be new to the British government, the problem isn’t. Crossing generational divides both loneliness and social isolation permeate throughout society, affecting people regardless of race, gender or social class. Importantly, loneliness and social isolation have been associated with negative impacts on health outcomes – and both are becoming increasingly prevalent among older adults. In the US, one-third of adults over the age of 60 are estimated to feel lonely and a quarter of over 65s live alone. Despite often being categorized as a social problem, the health implications caused by loneliness are significant. And as populations grow older, health-related issues associated with loneliness and social isolation are becoming more pertinent for healthcare services. It is estimated that by 2050, there will be 2.1 billion people aged 60 or over worldwide, representing 21.3 percent of the global population (1).

Though the terms are often used interchangeably, loneliness and social isolation are two uniquely distinct concepts that are based on individual experience. It is possible to be socially isolated and not have feelings of loneliness, and vice versa. Research has shown that many older adults who live in group settings (care homes) report loneliness.

Whether in conjunction with social isolation or not, self-perceived loneliness is detrimental to both physical and mental health. Many older adults who report feelings of loneliness also express feelings depression, lethargy and poor mental health. The sedentary lifestyle adopted by many lonely and/or isolated older adults is linked to poor physical health outcomes, including obesity, heart disease, diabetes, stroke, and even dementia and Alzheimer’s disease.

The lack of sound research and evidence-based studies on the interventions that help to reduce loneliness among older adults is concerning. For those of us engaged in public health and gerontology, it is essential to do more to fill the information gaps that hinder geriatric patient care.

There isn’t a drug in the world that can cure loneliness. Its treatment requires multifaceted interventions that consider both the older adult and their context. The pharma industry can support older patients who struggle with polypharmacy – and tackle adverse drug events that may exacerbate isolation and loneliness among this at-risk population.

Aging, loneliness and disease are all interconnected.  A more holistic approach to prescribing and managing medications can be developed to better match the needs of the patients most likely to take them – especially when they may be all alone. This has potential to extend and save lives.

Jessica Finlay is a postdoctoral fellow at the Institute for Social Research at the University of Michigan

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. ONS, “Living longer: how our population is changing and why it matters”. Available at https://bit.ly/2OxKFVc. Last Accessed January 15, 2019. Age UK, “Loneliness”. Available at https://bit.ly/2zWCHO4. Last accessed on January 15, 2019.

About the Author(s)

Jessica Finlay

Jessica Finlay is a postdoctoral fellow in the Institute for Social Research at the University of Michigan.

More Articles by Jessica Finlay

False

Advertisement

Recommended

False

Related Content

What About the Kids?
Formulation
What About the Kids?

December 3, 2014

0 min read

Since the late 1990s, new regulations have given us the opportunity to address the needs of the most vulnerable and demanding patients – children...

Squid-Inspired Drug Delivery
Drug Delivery Dosage Forms Formulation
Squid-Inspired Drug Delivery

April 3, 2025

4 min read

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally

Schizophrenia and the Future of Long-Acting Therapeutics
Formulation Dosage Forms Drug Delivery
Schizophrenia and the Future of Long-Acting Therapeutics

March 11, 2025

5 min read

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

The Power of Industry and Academic Collaboration
Drug Discovery Formulation
The Power of Industry and Academic Collaboration

March 13, 2025

6 min read

Purdue University’s Young Institute is tackling pharma’s toughest challenges— from mRNA stability to aseptic manufacturing.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.